Menu Back toSession-9-Track-3-The-Emerging-Role-of-Medical-Science-Liaisons-in-Clinical-Research

Medical Affairs and Scientific Communications Forum

3 Meetings, 1 Location: Medical Communications, Medical Science Liaisons, Medical Writing

Session 9 Track 3: The Emerging Role of Medical Science Liaisons in Clinical Research

Session Chair(s)

J. Lynn  Bass, PharmD, RPh

J. Lynn Bass, PharmD, RPh

  • Senior Director, Medical Sciences
  • Medexus Pharma, United States

In the recent past, the Medical Science Liaison (MSL) has been exposed to expanding and innovative opportunities within both medical and clinical affairs. Demonstrated success in clinical research is now a growing role for the MSL, as well as an interesting opportunity for the MSL to define their value proposition to a company. This is especially valuable if the MSL team of a given company can impact and shorten the development time for a given product. Through support of investigators from an educational perspective, the value of that effort by the MSL group can potentially translate into a value proposition for both the MSL team and medical affairs. This session will demonstrate best practices from across the industry on this growing opportunity for the MSL role in clinical development.

Learning Objective : At the end of this session, participants should be able to:
  • Illustrate appropriate role of the MSL in clinical development/operations
  • Discuss metrics for evaluating the MSL’s role in clinical studies
  • Evaluate future opportunities for collaboration between MSL teams and clinical development/operation


Susan  Shaffer, PharmD, MBA


Susan Shaffer, PharmD, MBA

  • Head of Global Medical Capabilities, Respiratory
  • AstraZeneca, United Kingdom
James  Walter, PhD


James Walter, PhD

  • National Team Leader, Cardiometabolic RSDs, US Medical Affairs
  • Merck Research Labs, United States